EntryPoint Capital LLC Has $276,000 Stake in Bioventus Inc. (NYSE:BVS)

EntryPoint Capital LLC reduced its holdings in Bioventus Inc. (NYSE:BVS) by 33.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,323 shares of the company’s stock after selling 12,979 shares during the quarter. EntryPoint Capital LLC’s holdings in Bioventus were worth $276,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Bioventus by 38.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after purchasing an additional 109,359 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Bioventus during the third quarter worth about $788,000. JPMorgan Chase & Co. increased its stake in Bioventus by 228.3% during the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock valued at $3,032,000 after acquiring an additional 176,442 shares during the period. State Street Corp raised its holdings in Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after acquiring an additional 189,216 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Bioventus by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after acquiring an additional 65,374 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bioventus

In other news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the sale, the chief financial officer now owns 118,817 shares of the company’s stock, valued at $1,210,745.23. This trade represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,161 shares of company stock worth $436,364 over the last three months. Company insiders own 32.90% of the company’s stock.

Bioventus Trading Down 0.7 %

BVS stock opened at $9.03 on Friday. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The business’s 50 day moving average is $10.07 and its 200-day moving average is $10.97. The firm has a market cap of $739.95 million, a P/E ratio of -14.80 and a beta of 0.86.

Analysts Set New Price Targets

A number of brokerages recently commented on BVS. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and upped their target price for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.